Novel screening test for celiac disease using peptide functionalised gold nanoparticles

Table 2 Analysis of 7 samples with potential or latent celiac disease using the Peptide-AuNP-anti-gliadin test as compared with previously existing serology¹

Volunteer	Histology	tTG-IgA	DGP-IgG	Peptide-AuNP-AGA
n.24	Mucosal lesions	5 (< 20)	17 (< 20)	CD positive
n.25	Mucosal lesions	28 (0-6)	22 (0-6)	CD positive
n.26	Mucosal lesions	4.8 (0-6)	22 (0-6)	CD positive
n.27	Increased γδ+ IELs	< 5 (< 5)	22 (< 20)	CD positive
n.28	Increased γδ+ IELs	12 (0-6)	18 (0-6)	CD positive
n.29	Increased γδ+ IELs	11 (0-6)	13 (0-6)	CD positive
n.30	Increased γδ+ IELs	< 5 (< 5)	< 20 (< 20)	CD positive

¹Serology tTG (tissue transglutaminase), deamidated gliadin peptides (deaminated gliadin peptides) results are indicated as IgA or IgG levels followed by normal reference ranges in brackets. Cases are separated into those showing histological observations of irregular/patchy mucosal lesions or those with mucosal inflammation resulting from an increase in γδ⁺ IELs.